Elena Izmailova PhD

Elena Izmailova is a clinical scientist with a unique background bridging technology innovation, scientific strategy, and business management. Her main interests lie in biomarker discovery, development, and utilization in the context of clinical trials. Elena is currently Chief Scientific Officer of Koneksa Health, an innovative technology company that accelerates the development of new medicines by leveraging wearable technologies to collect real-world data, enabling the biopharmaceutical industry to execute more efficient and successful clinical trials. Prior to her appointment with Koneksa Health, Elena led the wearable device clinical innovation group at Takeda Pharmaceuticals, where she created a comprehensive digital roadmap for technology-enabled clinical development. Elena joined the pharmaceutical industry in 2003.

At Millennium Pharmaceuticals she led cross-functional teams to develop and deploy clinical biomarker strategies and directed the bio-analysis function responsible for biomarker assay development, validation and implementation across multiple therapeutic areas and in global clinical trials. She additionally established fruitful collaborations with investigators at several major teaching hospitals, leading to discovery and characterization of novel disease biomarkers, and resulting in multiple publications and conference presentations. Elena holds a Ph.D. in Biology. She completed postdoctoral training at Massey Cancer Center/MCV and at Children’s Hospital/Harvard Medical School. She has also held a visiting scientist position at the Whitehead Institute of MIT.